Tens of thousands of Multiple Sclerosis sufferers could be denied drugs which can stop sufferers “screaming out” in pain, under new NHS recommendations, experts have warned.

Neurologists said the decision by the National Institute of Health and Care Excellence (NICE) to reject two drugs for symptoms of MS could leave thousands of patients suffering “horrendous” pain and immobility.

New draft guidelines on the diagnosis and care of people with MS have rejected two drugs which have been licensed in recent years to help sufferers experiencing spasticity and mobility problems.

In a letter to The Telegraph, the head of the MS Society and seven leading neurologists and pain management experts attacked the decision, criticising the rationing body for making decisions “behind closed doors” without involving those affected.

Experts accused NICE of rejecting the drugs Fampyra and Sativex, without taking proper account of the “life-changing” difference the drugs could make to up to 40,000 MS sufferers who are likely to develop mobility problems or painful spasms.

For more details, go to: http://www.telegraph.co.uk/health/healthnews/10884888/Anger-over-decision-to-refuse-patients-MS-drugs.html